Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Purchased by Bank of Montreal Can

Bank of Montreal Can lifted its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 20.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 48,026 shares of the company’s stock after buying an additional 8,084 shares during the period. Bank of Montreal Can’s holdings in Roivant Sciences were worth $568,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Barclays PLC grew its holdings in Roivant Sciences by 19.7% during the 3rd quarter. Barclays PLC now owns 459,521 shares of the company’s stock valued at $5,302,000 after purchasing an additional 75,609 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Roivant Sciences in the 3rd quarter valued at approximately $207,000. Te Ahumairangi Investment Management Ltd boosted its stake in shares of Roivant Sciences by 19.9% during the 3rd quarter. Te Ahumairangi Investment Management Ltd now owns 201,612 shares of the company’s stock valued at $2,313,000 after buying an additional 33,467 shares during the last quarter. Tyro Capital Management LLC grew its position in shares of Roivant Sciences by 0.6% during the third quarter. Tyro Capital Management LLC now owns 1,754,976 shares of the company’s stock worth $20,252,000 after buying an additional 10,649 shares in the last quarter. Finally, Retirement Systems of Alabama raised its holdings in Roivant Sciences by 26.9% in the third quarter. Retirement Systems of Alabama now owns 530,022 shares of the company’s stock valued at $6,116,000 after acquiring an additional 112,286 shares in the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on ROIV shares. Cantor Fitzgerald raised shares of Roivant Sciences to a “strong-buy” rating in a research report on Tuesday, March 4th. HC Wainwright reiterated a “buy” rating and issued a $18.00 price target on shares of Roivant Sciences in a report on Tuesday, February 11th.

Insider Activity

In other Roivant Sciences news, COO Eric Venker sold 434,478 shares of the business’s stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $10.82, for a total value of $4,701,051.96. Following the sale, the chief operating officer now directly owns 1,127,290 shares in the company, valued at approximately $12,197,277.80. The trade was a 27.82 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Rakhi Kumar sold 227,500 shares of the company’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the completion of the sale, the chief accounting officer now directly owns 163,264 shares of the company’s stock, valued at $1,702,843.52. The trade was a 58.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,395,541 shares of company stock valued at $15,028,538. Insiders own 7.90% of the company’s stock.

Roivant Sciences Stock Up 1.3 %

Shares of ROIV stock opened at $10.15 on Monday. The business has a 50 day moving average of $10.33 and a two-hundred day moving average of $11.17. The company has a market cap of $7.24 billion, a P/E ratio of -67.66 and a beta of 1.25. Roivant Sciences Ltd. has a 52 week low of $8.73 and a 52 week high of $13.06.

Roivant Sciences (NASDAQ:ROIV) last posted its earnings results on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. Analysts expect that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.